CureVac N.V. Ordinary Shares (CVAC) Dividend History

Company News

• Flu RNA Vaccines Market Research Report 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges

  The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.

  GlobeNewswire Inc.

  Featured Companies: ARCT MRNA PFE
• Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive

  While smaller deals have been completed, including overseas acquisitions, the expected surge in large-scale mergers and acquisitions has not materialized. Factors like trade policy uncertainty and economic concerns have kept corporate decision-makers cautious about striking major deals.

  Investing.com

  Featured Companies: BRO CRM CRWV DKS
• BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

  BioNTech has agreed to acquire CureVac in an all-stock transaction valued at around $1.25 billion. The deal aims to strengthen BioNTech's research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy.

  Benzinga
• Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

  The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

  Zacks Investment Research

  Featured Companies: MRNA NVAX PFE
• Wall Street Breakfast Podcast: Nvidia Soars On Strong Earnings, Guidance, And Stock Split

  Nvidia gains as Q1 results, guidance top expectations; announces 10-1 split. Live Nation sinks 7% on report DOJ antitrust action is ready. Moderna, BioNTech close double-digits.

  Seeking Alpha

  Featured Companies: LYV MRNA NVDA